The Advanced Endoscopy Innovation Translation and Clinical Trials Group Laboratory, led by Barham K. Abu Dayyeh, M.D., M.P.H., focuses on the development of minimally invasive endoscopic therapies for gastrointestinal diseases, obesity and metabolic diseases.
Dr. Abu Dayyeh and his research team are investigating several ongoing studies and projects.
Primary Obesity Surgery Endoluminal (POSE 2.0)
POSE 2.0 is a novel endoscopic procedure that aims to create a gastric physiology where the stomach is narrower and shorter. This novel procedure involves creating an average of 20 plications in the stomach from the incisura to the cardia at the gastroesophageal junction. Each plication is anchored between two snowshoe anchors along six tissue folds of the stomach.
POSE 2.0 is an expansion from a previous trial in 2019 (POSE) that included placing sutures at the fundus of the stomach. This is no longer used.
CTIF vs. LNF for the treatment of GERD in patients with hiatal hernia
A multicenter, single-blind, randomized clinical controlled trial comparing the efficacy and safety of laparoscopic Nissen fundoplication (LNF) versus laparoscopic hiatal hernia repair combined with transoral incisionless fundoplication (CTIF) for the treatment of GERD in patients requiring a hiatal hernia repair. A total of seven centers across the United States are participating in this trial, with a target enrollment of around 140 patients.
Prediction of GERD after laparoscopic sleeve gastroplasty using endoflip
This multicenter, prospective study aims to identify a predictive model for worsening of preexisting GERD or the development of de novo GERD after laparoscopic sleeve gastrectomy using the EndoFlip device.
Multicenter Endoscopic Sleeve Gastrectomy (ESG) Trial (MERIT Trial)
This multicenter, randomized, open-label clinical trial evaluates the efficacy and safety of endoscopic sleeve gastroplasty (ESG). The study evaluates ESG as an adjunct to lifestyle intervention for weight loss and improvement in obesity-related comorbidities compared to lifestyle intervention alone in participants with a BMI ≥ 30 and ≤40 kg/m² who have failed to achieve and maintain weight loss with a nonsurgical program.